CN115297877A - 肾脏中cd25阳性调节性t细胞增加剂 - Google Patents

肾脏中cd25阳性调节性t细胞增加剂 Download PDF

Info

Publication number
CN115297877A
CN115297877A CN202180021798.6A CN202180021798A CN115297877A CN 115297877 A CN115297877 A CN 115297877A CN 202180021798 A CN202180021798 A CN 202180021798A CN 115297877 A CN115297877 A CN 115297877A
Authority
CN
China
Prior art keywords
cells
mesenchymal stem
stem cells
regulatory
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021798.6A
Other languages
English (en)
Chinese (zh)
Inventor
丸山彰一
古桥和扩
田中章仁
唐泽宗稔
高尾幸成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University Corp Donghai National University
Rohto Pharmaceutical Co Ltd
Original Assignee
National University Corp Donghai National University
Rohto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corp Donghai National University, Rohto Pharmaceutical Co Ltd filed Critical National University Corp Donghai National University
Publication of CN115297877A publication Critical patent/CN115297877A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180021798.6A 2020-04-13 2021-04-09 肾脏中cd25阳性调节性t细胞增加剂 Pending CN115297877A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-071737 2020-04-13
JP2020071737 2020-04-13
PCT/JP2021/015093 WO2021210515A1 (ja) 2020-04-13 2021-04-09 腎臓中のｃｄ２５陽性の制御性ｔ細胞増加剤

Publications (1)

Publication Number Publication Date
CN115297877A true CN115297877A (zh) 2022-11-04

Family

ID=78084239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021798.6A Pending CN115297877A (zh) 2020-04-13 2021-04-09 肾脏中cd25阳性调节性t细胞增加剂

Country Status (5)

Country Link
US (1) US20230158076A1 (https=)
EP (1) EP4137141A4 (https=)
JP (1) JPWO2021210515A1 (https=)
CN (1) CN115297877A (https=)
WO (1) WO2021210515A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039104A1 (en) * 1996-04-17 1997-10-23 Osiris Therapeutics, Inc. Cryopreservation and extensive subculturing of human mesenchymal stem cells
CN101384702A (zh) * 2004-03-22 2009-03-11 奥西里斯治疗公司 间充质干细胞及其用途
WO2017144552A1 (en) * 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
CN108699524A (zh) * 2016-02-26 2018-10-23 Scm生命科学有限公司 调节t细胞介导性疾病的预防或治疗用药剂学组合物
CN110177872A (zh) * 2017-03-03 2019-08-27 日本乐敦制药株式会社 间充质干细胞和药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
KR20160092038A (ko) * 2006-10-02 2016-08-03 메조블라스트 인터내셔널 에스에이알엘 중간엽 줄기 세포 및 그에 대한 용도
WO2011043136A1 (ja) * 2009-10-08 2011-04-14 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する免疫抑制剤及びその用途
SI2785359T1 (sl) * 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
CN109195445A (zh) * 2016-03-28 2019-01-11 库克通用生物技术有限责任公司 活细胞组合物及其相关方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039104A1 (en) * 1996-04-17 1997-10-23 Osiris Therapeutics, Inc. Cryopreservation and extensive subculturing of human mesenchymal stem cells
CN101384702A (zh) * 2004-03-22 2009-03-11 奥西里斯治疗公司 间充质干细胞及其用途
WO2017144552A1 (en) * 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
CN108699524A (zh) * 2016-02-26 2018-10-23 Scm生命科学有限公司 调节t细胞介导性疾病的预防或治疗用药剂学组合物
CN110177872A (zh) * 2017-03-03 2019-08-27 日本乐敦制药株式会社 间充质干细胞和药物组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUSTIN THIEL等: "Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritis", SCIENTIFIC REPORTS, vol. 5, 2 December 2015 (2015-12-02), pages 1 - 13 *
TAIHEI SUZUKI等: "Therapeutic effects of human mesenchymal stem cells in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis", PLOS ONE, vol. 8, no. 6, 24 June 2013 (2013-06-24), pages 1 - 12 *

Also Published As

Publication number Publication date
WO2021210515A1 (ja) 2021-10-21
EP4137141A1 (en) 2023-02-22
US20230158076A1 (en) 2023-05-25
EP4137141A4 (en) 2024-04-24
JPWO2021210515A1 (https=) 2021-10-21

Similar Documents

Publication Publication Date Title
JP5805195B2 (ja) Ｎｏｄ２アゴニストで処理した幹細胞またはその培養物を含む免疫疾患および炎症性疾患の予防および治療用の薬学的組成物
ES2769778T3 (es) Composiciones inmunomoduladoras
JP5431146B2 (ja) 免疫学的寛容および調節性前駆細胞
CN113559126A (zh) 利用胎盘干细胞治疗疼痛
KR102213527B1 (ko) 패혈증 치료용 중간엽 기질세포
JP2022084665A (ja) 脂肪由来幹細胞に基づく幹細胞治療
CN105934155A (zh) 在调节疼痛和/或纤维化中使用脂肪组织来源的细胞的方法
US20120100108A1 (en) Compositions and methods of treating no-option critical limb ischemia (cli)
JP7773294B2 (ja) 拡張型心筋症治療剤
EP3381458B1 (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
JP2024519222A (ja) ＮＫ細胞の凍結保存用組成物及びこれを含む凍結保存剤形｛ＮＫ ｃｅｌｌ ｃｒｙｏｐｒｅｓｅｒｖａｔｉｏｎ ｃｏｍｐｏｓｉｔｉｏｎ ａｎｄ ｃｒｙｏｐｒｅｓｅｒｖａｔｉｏｎ ｆｏｒｍｕｌａｔｉｏｎ ｃｏｍｐｒｉｓｉｎｇ ｔｈｅ ｓａｍｅ｝
JP7117704B1 (ja) 糖尿病の予防及び／又は治療剤
CN115297877A (zh) 肾脏中cd25阳性调节性t细胞增加剂
HK40078040A (en) Agent for increasing cd25-positive regulatory t cells in kidney
JP5753874B2 (ja) 細胞生存率低下抑制剤
CN110177871A (zh) 间充质干细胞和肝疾病治疗剂
WO2022176735A1 (ja) 糖尿病の予防及び／又は治療剤
JP7495075B2 (ja) 高血圧性心疾患治療剤
WO2018123627A1 (ja) 細胞医薬組成物、疾患治療用キット及び細胞懸濁用溶液
HK40082460A (en) Prophylactic and/or therapeutic agent for diabetes
WO2018123628A1 (ja) 細胞医薬組成物、疾患治療用キット及び細胞懸濁用溶液
US20130142762A1 (en) Methods of cardiac repair
JP2025095535A (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法
TW202608458A (zh) 癌症治療劑
JP2026007803A (ja) 腫瘍の治療剤及び腫瘍の予防剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078040

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination